By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Valeant Pharmaceuticals International 

Worldwide Headquarters
One Enterprise
Aliso Viejo  California  92656  U.S.A.
Phone: 800-548-5100 or 949-461-6000 Fax: 714-556-0131


SEARCH JOBS

Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

YEAR FOUNDED:

1960

LEADERSHIP:

CEO: Joseph C. Papa

CMO: Tage Ramakrishna

CFO: Robert Rosiello

CLINICAL TRIAL:

Please click here for clinical trial information.

JOB OPPORTUNITY:

Please click here for Valeant job opportunities.


Key Statistics


Email:
Ownership: Public

Web Site: Valeant
Employees: 12784
Symbol: VRX
 



Industry
Pharmaceutical


Collaborations

Metabasis Therapeutics, Inc.  – Hepatitis B





Company News
Valeant (VRX) Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications 6/20/2017 7:02:43 AM
Valeant (VRX) Surges As Its Largest Shareholder Joins Board 6/19/2017 6:08:05 AM
Valeant (VRX): Was iNova Pharma Sale The Worst Deal Ever? 6/19/2017 5:54:48 AM
The Not-So-Subtle Reason Behind Valeant (VRX)' 30% Rise In May 6/8/2017 6:43:52 AM
Debt-Laden Valeant (VRX) Unloads iNova Pharma In $930 Million Deal 6/8/2017 5:57:58 AM
Debt-Ridden Valeant (VRX) Nears Sale of Its $2 Billion Eye Care Biz Bausch & Lomb 6/7/2017 6:17:31 AM
68 Hedge Funds Buy Valeant (VRX) For The First Time 5/31/2017 6:48:16 AM
Why Valeant (VRX) CEO Thinks Johnson & Johnson (JNJ) Should Foot The Bill For Their Talc Defense 5/25/2017 6:41:04 AM
EyeGate Pharma Receives Milestone Payment From Valeant (VRX) For EGP-437 For Post-Operative Ocular Inflammation And Pain In Ocular Surgery Patients 5/22/2017 6:35:04 AM
Valeant (VRX) Release: Statement Regarding Xifaxan Intellectual Property Litigation 5/17/2017 9:12:00 AM
12345678910...
//-->